Alzheimer’s Aducanumab Redosing Study Underway


„Based on a larger dataset after the trials were terminated, it was determined that the assumptions in the futility analysis were not valid,“ said Carmen CastrilloViguera, MD, medical director of clinical development at Biogen, during a poster presentation at the American Academy of Neurology virtual meeting.